Formaldehyde Dehydrogenase – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)- Pipeline Review, H2 2019’, provides in depth analysis on Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Respiratory, Cardiovascular, Immunology, Gastrointestinal and Metabolic Disorders under development targeting Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)

– The report reviews Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics and enlists all their major and minor projects

– The report assesses Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics”

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Glenmark Pharmaceuticals Ltd

Saje Pharma LLC”

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) Overview 6

Therapeutics Development 7

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Products under Development by Stage of Development 7

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Products under Development by Therapy Area 8

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Products under Development by Indication 9

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Products under Development by Companies 12

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Companies Involved in Therapeutics Development 19

Nivalis Therapeutics, Inc. 19

Saje Pharma, LLC 20

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Drug Profiles 21

cavosonstat - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

SPL-227.1 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

SPL-334 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

SPL-334.1 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

SPL-875.1 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

SPL-891.1 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Dormant Projects 28

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Discontinued Products 30

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC

1.2.1.46) - Featured News & Press Releases 31

Jul 07, 2016: Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis 31

May 16, 2016: Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis 31

Apr 05, 2016: Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis 32

Mar 07, 2016: Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis 32

Mar 01, 2016: Nivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors 33

Feb 29, 2016: Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results 34

Feb 18, 2016: Nivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis 35

Jan 15, 2016: Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis 36

Dec 01, 2015: Nivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis 36

Oct 07, 2015: Nivalis Therapeutics Announces Positive Phase 1b Results for N91115 in Patients With Cystic Fibrosis and Plans to Initiate Phase 2 Trial 37

Mar 14, 2014: N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy 38

Mar 12, 2014: N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Glenmark Pharmaceuticals Ltd, H2 2019

Pipeline by Saje Pharma LLC, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports